Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Upwork participates in a conference call with JMP Securities » 04:55
08/07/20
08/07
04:55
08/07/20
04:55
UPWK

Upwork

$13.90 /

-1.18 (-7.82%)

Conference call with…

Conference call with management will be held on August 7 hosted by JMP Securities.

ShowHide Related Items >><<
UPWK Upwork
$13.90 /

-1.18 (-7.82%)

UPWK Upwork
$13.90 /

-1.18 (-7.82%)

07/01/20 BTIG
Upwork price target raised to $16 from $14 at BTIG
03/19/20 JMP Securities
Upwork price target lowered to $11 from $19 at JMP Securities
02/27/20 RBC Capital
Upwork price target lowered to $14 from $20 at RBC Capital
02/27/20 BTIG
Upwork price target lowered to $14 from $20 at BTIG
UPWK Upwork
$13.90 /

-1.18 (-7.82%)

UPWK Upwork
$13.90 /

-1.18 (-7.82%)

UPWK Upwork
$13.90 /

-1.18 (-7.82%)

UPWK Upwork
$13.90 /

-1.18 (-7.82%)

Thursday
Syndicate
Kura Oncology files $300M mixed securities shelf  16:35
08/06/20
08/06
16:35
08/06/20
16:35
KURA

Kura Oncology

$17.99 /

+0.34 (+1.93%)

 
ShowHide Related Items >><<
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

  • 06
    May
Earnings
Kura Oncology reports Q EPS (40c), consensus (42c) » 16:26
08/06/20
08/06
16:26
08/06/20
16:26
KURA

Kura Oncology

$17.99 /

+0.34 (+1.93%)

Cash, cash equivalents…

Cash, cash equivalents and short-term investments totaled $338.9M as of June 30, including net proceeds of approximately $134.9M from a public offering completed in May, compared with $236.9M as of December 31, 2019. "Last quarter we implemented a number of strategic measures to focus on our two major development pillars: tipifarnib in HRAS-dependent head and neck squamous cell carcinoma (HNSCC) and KO-539 in acute myeloid leukemia (AML)," said Troy Wilson, CEO of Kura Oncology. "We believe tipifarnib and KO-539 provide opportunities to address large proportions of head and neck cancers and acute leukemias, respectively. Now, following a successful public offering this past quarter, we are well-positioned to advance each of these programs toward important upcoming catalysts."

ShowHide Related Items >><<
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

  • 06
    May
Conference/Events
Upwork participates in a conference call with JMP Securities » 11:49
08/06/20
08/06
11:49
08/06/20
11:49
UPWK

Upwork

$14.07 /

-1.015 (-6.73%)

Conference call with…

Conference call with management will be held on August 7 hosted by JMP Securities.

ShowHide Related Items >><<
UPWK Upwork
$14.07 /

-1.015 (-6.73%)

UPWK Upwork
$14.07 /

-1.015 (-6.73%)

07/01/20 BTIG
Upwork price target raised to $16 from $14 at BTIG
03/19/20 JMP Securities
Upwork price target lowered to $11 from $19 at JMP Securities
02/27/20 RBC Capital
Upwork price target lowered to $14 from $20 at RBC Capital
02/27/20 BTIG
Upwork price target lowered to $14 from $20 at BTIG
UPWK Upwork
$14.07 /

-1.015 (-6.73%)

UPWK Upwork
$14.07 /

-1.015 (-6.73%)

UPWK Upwork
$14.07 /

-1.015 (-6.73%)

UPWK Upwork
$14.07 /

-1.015 (-6.73%)

Initiation
Fly Intel: Top analyst initiations » 10:02
08/06/20
08/06
10:02
08/06/20
10:02
LI

Li Auto

$16.98 /

+0.23 (+1.37%)

, YUMC

Yum China

$53.47 /

+0.22 (+0.41%)

, ZYME

Zymeworks

$30.61 /

-0.44 (-1.42%)

, DLR

Digital Realty

$159.48 /

-0.18 (-0.11%)

, CONE

CyrusOne

$86.36 /

-0.14 (-0.16%)

, EQIX

Equinix

$793.38 /

-1.13 (-0.14%)

Catch up on today's…

Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Li Auto (LI) initiated with an Outperform at Bernstein. 2. Yum China (YUMC) initiated with a Buy at CLSA. 3. Zymeworks (ZYME) initiated with an Outperform at SVB Leerink. 4. CyrusOne (CONE) was initiated with a Buy at TD Securities while Digital Realty (DLR) and Equinix (EQIX) were initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
ZYME Zymeworks
$30.61 /

-0.44 (-1.42%)

YUMC Yum China
$53.47 /

+0.22 (+0.41%)

EQIX Equinix
$793.38 /

-1.13 (-0.14%)

DLR Digital Realty
$159.48 /

-0.18 (-0.11%)

CONE CyrusOne
$86.36 /

-0.14 (-0.16%)

LI Li Auto
$16.98 /

+0.23 (+1.37%)

08/06/20 Bernstein
Li Auto initiated with an Outperform at Bernstein
YUMC Yum China
$53.47 /

+0.22 (+0.41%)

08/06/20 CLSA
Yum China initiated with a Buy at CLSA
07/30/20 Jefferies
Yum China price target raised to $62 from $59 at Jefferies
04/29/20 Daiwa
Yum China upgraded to Outperform from Neutral at Daiwa
02/06/20 Daiwa
Yum China downgraded to Hold from Outperform at Daiwa
ZYME Zymeworks
$30.61 /

-0.44 (-1.42%)

08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
07/14/20 Guggenheim
Zymeworks price target lowered to $48, removed as Best Idea at Guggenheim
07/13/20 Canaccord
Zymeworks price target raised to $42 from $25 at Canaccord
DLR Digital Realty
$159.48 /

-0.18 (-0.11%)

08/06/20 TD Securities
Digital Realty initiated with a Hold at TD Securities
07/31/20 Raymond James
Digital Realty upgraded to Outperform from Market Perform at Raymond James
07/31/20 Raymond James
Digital Realty upgraded to Outperform from Market Perform at Raymond James
07/15/20 Barclays
Digital Realty initiated with an Overweight at Barclays
CONE CyrusOne
$86.36 /

-0.14 (-0.16%)

08/06/20 TD Securities
CyrusOne initiated with a Buy at TD Securities
08/04/20 Credit Suisse
CyrusOne price target raised to $92 from $78 at Credit Suisse
08/03/20 Deutsche Bank
CyrusOne price target raised to $88 from $83 at Deutsche Bank
07/15/20 Truist
CyrusOne price target raised to $90 from $82 at SunTrust
EQIX Equinix
$793.38 /

-1.13 (-0.14%)

08/06/20 TD Securities
Equinix initiated with a Hold at TD Securities
08/05/20 Deutsche Bank
Equinix price target raised to $850 from $760 at Deutsche Bank
07/30/20 Wells Fargo
Equinix price target raised to $840 from $790 at Wells Fargo
07/30/20 JPMorgan
Equinix price target raised to $861 from $725 at JPMorgan
ZYME Zymeworks
$30.61 /

-0.44 (-1.42%)

YUMC Yum China
$53.47 /

+0.22 (+0.41%)

EQIX Equinix
$793.38 /

-1.13 (-0.14%)

DLR Digital Realty
$159.48 /

-0.18 (-0.11%)

CONE CyrusOne
$86.36 /

-0.14 (-0.16%)

  • 30
    Jul
  • 12
    May
  • 23
    Jan
YUMC Yum China
$53.47 /

+0.22 (+0.41%)

EQIX Equinix
$793.38 /

-1.13 (-0.14%)

DLR Digital Realty
$159.48 /

-0.18 (-0.11%)

CONE CyrusOne
$86.36 /

-0.14 (-0.16%)

YUMC Yum China
$53.47 /

+0.22 (+0.41%)

LI Li Auto
$16.98 /

+0.23 (+1.37%)

CONE CyrusOne
$86.36 /

-0.14 (-0.16%)

YUMC Yum China
$53.47 /

+0.22 (+0.41%)

EQIX Equinix
$793.38 /

-1.13 (-0.14%)

DLR Digital Realty
$159.48 /

-0.18 (-0.11%)

Initiation
SVB Leerink bullish on Zymeworks, initiates with an Outperform » 09:25
08/06/20
08/06
09:25
08/06/20
09:25
ZYME

Zymeworks

/

+

As previously reported,…

As previously reported, SVB Leerink analyst Andrew Berens initiated coverage of Zymeworks with an Outperform rating and $45 price target. The analyst notes that Zymeworks as several promising assets in the clinic, as well as a robust drug development platform that focuses on protein engineering. The company's lead asset, zanidatamab, is a bispecific antibody that targets the HER2 pathway, with physiological activity that appears to exceed that of the 2-drug regimen of Herceptin and Perjeta, leveraging the biparatopic features designed into the protein, he adds. Berens also points out that the company also has a HER2 antibody drug conjugate, ZW49, that is in clinical testing. While he is hopeful that ZW49 eventually reaches fruition, Berens believes that the current skepticism around the drug has created a very favorable entry point for investors ahead of several meaningful catalysts.

ShowHide Related Items >><<
ZYME Zymeworks
/

+

ZYME Zymeworks
/

+

08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
07/14/20 Guggenheim
Zymeworks price target lowered to $48, removed as Best Idea at Guggenheim
07/13/20 Canaccord
Zymeworks price target raised to $42 from $25 at Canaccord
07/09/20 H.C. Wainwright
Zymeworks 'evasiveness' not what Street wanted, says H.C. Wainwright
ZYME Zymeworks
/

+

  • 23
    Jan
Hot Stocks
GrafTech expects demand to 'remain low for the remainder of 2020' » 06:42
08/06/20
08/06
06:42
08/06/20
06:42
EAF

GrafTech

$6.48 /

+0.26 (+4.18%)

GrafTech said, "The…

GrafTech said, "The second half of 2020 will continue to be challenging as we and our customers face macro-economic headwinds. We foresee a measured recovery in the industry when the pandemic eases as customers work through inventory levels that were elevated prior to the onset of the pandemic. We expect overall demand and pricing to remain low for the remainder of 2020. We have full confidence in the strengths of the Electric Arc Furnace and graphite electrode businesses. The environmental and economic attributes of these industries are key advantages and position them for continued growth over the longer term. We believe GrafTech is well positioned to navigate the challenges of the current environment and the opportunities in the future recovery given our leadership position in the industry, our strong cash flows, and our advantaged cost position."

ShowHide Related Items >><<
EAF GrafTech
$6.48 /

+0.26 (+4.18%)

EAF GrafTech
$6.48 /

+0.26 (+4.18%)

02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
12/17/19 BMO Capital
GrafTech downgraded to Market Perform from Outperform at BMO Capital
EAF GrafTech
$6.48 /

+0.26 (+4.18%)

  • 05
    Dec
EAF GrafTech
$6.48 /

+0.26 (+4.18%)

EAF GrafTech
$6.48 /

+0.26 (+4.18%)

Earnings
GrafTech reports Q2 EPS 35c, consensus 22c » 06:41
08/06/20
08/06
06:41
08/06/20
06:41
EAF

GrafTech

$6.48 /

+0.26 (+4.18%)

Reports Q2 revenue…

Reports Q2 revenue $280.7M, consensus $226.33M.

ShowHide Related Items >><<
EAF GrafTech
$6.48 /

+0.26 (+4.18%)

EAF GrafTech
$6.48 /

+0.26 (+4.18%)

02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
12/17/19 BMO Capital
GrafTech downgraded to Market Perform from Outperform at BMO Capital
EAF GrafTech
$6.48 /

+0.26 (+4.18%)

  • 05
    Dec
EAF GrafTech
$6.48 /

+0.26 (+4.18%)

EAF GrafTech
$6.48 /

+0.26 (+4.18%)

Initiation
Zymeworks initiated with an Outperform at SVB Leerink » 06:12
08/06/20
08/06
06:12
08/06/20
06:12
ZYME

Zymeworks

$31.05 /

-0.41 (-1.30%)

SVB Leerink initiated…

SVB Leerink initiated coverage of Zymeworks with an Outperform rating and $45 price target.

ShowHide Related Items >><<
ZYME Zymeworks
$31.05 /

-0.41 (-1.30%)

ZYME Zymeworks
$31.05 /

-0.41 (-1.30%)

07/14/20 Guggenheim
Zymeworks price target lowered to $48, removed as Best Idea at Guggenheim
07/13/20 Canaccord
Zymeworks price target raised to $42 from $25 at Canaccord
07/09/20 H.C. Wainwright
Zymeworks 'evasiveness' not what Street wanted, says H.C. Wainwright
03/03/20 H.C. Wainwright
Zymeworks price target lowered to $60 from $65 at H.C. Wainwright
ZYME Zymeworks
$31.05 /

-0.41 (-1.30%)

  • 23
    Jan
Wednesday
Earnings
Zymeworks reports Q2 EPS (77c), consensus (67c) » 16:23
08/05/20
08/05
16:23
08/05/20
16:23
ZYME

Zymeworks

$31.20 /

-0.26 (-0.83%)

"Among many notable…

"Among many notable accomplishments in the past quarter, I am particularly excited about the transition of our lead therapeutic program, zanidatamab, into late stage clinical development, providing a clear path for Zymeworks to seek its first potential approval in biliary tract cancer in 2022," said Ali Tehrani, Ph.D., Zymeworks' President & CEO. "Looking ahead, with zanidatamab in five active Phase 2 programs and ZW49 advancing in its dose-escalation study, we anticipate a number of important data readouts over the next six to twelve months. We are proud of everything that we have accomplished and are well positioned to strategically execute on our mission of sending patients home to their loved ones, disease free."

ShowHide Related Items >><<
ZYME Zymeworks
$31.20 /

-0.26 (-0.83%)

ZYME Zymeworks
$31.20 /

-0.26 (-0.83%)

07/14/20 Guggenheim
Zymeworks price target lowered to $48, removed as Best Idea at Guggenheim
07/13/20 Canaccord
Zymeworks price target raised to $42 from $25 at Canaccord
07/09/20 H.C. Wainwright
Zymeworks 'evasiveness' not what Street wanted, says H.C. Wainwright
03/03/20 H.C. Wainwright
Zymeworks price target lowered to $60 from $65 at H.C. Wainwright
ZYME Zymeworks
$31.20 /

-0.26 (-0.83%)

  • 23
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.